Femasys Q3 net loss widens to $4.0M, revenue down 30%; FemaSeed gets FDA clearance

FEMASYS INC

2023-Q3 EPS reported -$0.74 revenue$858,859

Net loss of $4.0M ($0.26/share) vs $3.0M ($0.25) in Q3 2022.
Revenue $244K, down 30% from $347K; U.S. units down 18.4% YoY.
Raised $11.3M via warrant exercises and ATM; cash $8.7M sufficient for >12 months.
FDA 510(k) clearance for FemaSeed infertility treatment; FINALE trial for FemBloc enrolling.
Gross margin improved to 64.7% from 62.2% on manufacturing efficiencies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

FEMASYS INC reported the third quarter ended September 30, 2023 results: revenue $244,361.

Period: the third quarter ended September 30, 2023
Revenue: $244,361
Result: reported results

Exact text from the filing

2022. The increase was largely due to increased compensation and professional costs, partially offset by decreased facility and overhead costs. • Sales decreased by $103,095 to $244,361 for the three months ended September 30, 2023 compared

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-053088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.